Download MendeleyDiscovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.
Boezio, A.A., Copeland, K.W., Rex, K., K Albrecht, B., Bauer, D., Bellon, S.F., Boezio, C., Broome, M.A., Choquette, D., Coxon, A., Dussault, I., Hirai, S., Lewis, R., Lin, M.H., Lohman, J., Liu, J., Peterson, E.A., Potashman, M., Shimanovich, R., Teffera, Y., Whittington, D.A., Vaida, K.R., Harmange, J.C.(2016) J Med Chem 59: 2328-2342
- PubMed: 26812066
- DOI: https://doi.org/10.1021/acs.jmedchem.5b01716
- Primary Citation of Related Structures:
5EYC, 5EYD - PubMed Abstract:
Deregulation of the receptor tyrosine kinase mesenchymal epithelial transition factor (MET) has been implicated in several human cancers and is an attractive target for small molecule drug discovery. Herein, we report the discovery of compound 23 (AMG 337), which demonstrates nanomolar inhibition of MET kinase activity, desirable preclinical pharmacokinetics, significant inhibition of MET phosphorylation in mice, and robust tumor growth inhibition in a MET-dependent mouse efficacy model.
Organizational Affiliation:
Amgen Incorporated , One Amgen Center Drive, Thousand Oaks, California 91320, United States.
